<DOC>
	<DOC>NCT00562731</DOC>
	<brief_summary>Male hypogonadism, a disorder associated with testosterone deficiency, is frequently seen in clinical practice and has significant effects on patient well-being. The purpose of this study is to investigate the efficacy and safety of ARD-0403 as a testosterone replacement therapy in testosterone deficient men.</brief_summary>
	<brief_title>Open-Label Study of ARD-0403 in Testosterone Deficient Men</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Testosterone deficiency Completed study ARD0403004 Previous treatment with testosterone replacement therapy within 4 weeks Moderatesevere benign prostatic hypertrophy or prostatic cancer Haematocrit &gt;50%</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>